Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function

Antioxidants and Redox Signaling

Volumn 7, Issue 11-12, 2005, Pages 1476-1482

  Callaghan, Matthew J ^a   Ceradini, Daniel J ^a   Gurtner, Geoffrey C ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; UBIQUINONE;

ANGIOGENESIS; BONE MARROW CELL; DIABETES MELLITUS; ENDOTHELIUM CELL; GENE EXPRESSION; GLUCOSE INTAKE; HUMAN; HYPERGLYCEMIA; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; VASCULAR DISEASE;

ANIMALS; DIABETES MELLITUS; ENDOTHELIAL CELLS; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; STEM CELLS;

EID: 28844434974     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1476     Document Type: Review

References (57)

1. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, and Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99: 2239-2242, 1999.
2. Al Shamsi MS, Amin A, and Adeghate E. Beneficial effect of vitamin E on the metabolic parameters of diabetic rats. Mol Cell Biochem 261: 35-42, 2004.
3. Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodato B, Colonna M, Torre V, Russo G, Sardella A, Urna G, Campo GM, Cavallari V, Squadrito G, and Squadrito F. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 50: 661-614, 2001.
4. Amos AF, McCarty DJ. and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl 5: S1-S85, 1997.
5. Asahara T and Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 287: C572-C579, 2004.
6. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997.
7. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, and Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228, 1999.
8. Ausprunk DH and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65, 1977.
9. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, de Sauvage F, and Rafii S. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10: 64-71, 2004.
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
11. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, and Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333: 283-287, 1995.
12. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, and Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
13. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, and Bowen-Pope DF. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87: 728-730, 2000.
14. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, and Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 104: 3591-3597, 2004.
15. Domenick MA and Ildstad ST. Impact of bone marrow transplantation on type I diabetes. World J Surg 25: 474-480, 2001.
16. Echtay KS, Murphy MP, Smith RA, Talbot DA, and Brand MD. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem 277: 47129-47135, 2002.
17. Edelberg JM, Tang L, Hattori K, Lyden D, and Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 90: E89-E93, 2002.
18. Edsmyr F, Huber W, and Menander KB. Orgotein efficacy in ameliorating side effects due to radiation therapy. I. Double-blind, placebo-controlled trial in patients with bladder tumors. Curr Ther Res Clin Exp 19: 198-211, 1976.
19. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, and Gurtner GC. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164: 1935-1947, 2004.
20. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, and Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95: 3106-3112, 2000.
21. Giugliano D, Ceriello A, and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
22. Goebel KM, Storck U, and Neurath F. Intrasynovial orgotein therapy in rheumatoid arthritis. Lancet 1: 1015-1017, 1981.
23. Green K, Brand MD, and Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53 Suppl 1: S110-S118, 2004.
24. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, and Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294-299, 2003.
25. Harper JA, Dickinson K, and Brand MD. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2: 255-265, 2001.
26. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, and Carothers J. Bone marrow as a source of endothelial cells and neun-expressing cells after stroke. Stroke 33: 1362-1368, 2002.
27. Housset M, Baillet F, Michelson AM, and Puget K. [Action of liposomal superoxide dismutase on measurable radiation-induced fibrosis.] Ann Med Interne (Paris) 140: 365-367, 1989.
28. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, and Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105: 732-738, 2002.
29. Jauslin ML, Meier T, Smith RA, and Murphy MP. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17: 1972-1974, 2003.
30. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, and Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276: 4588-4596, 2001.
31. Kessinger A and Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77: 211-213, 1991.
32. Marberger H, Huber W, Bartsch G, Schulte T, and-Swoboda P. Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Int Urol Nephrol 6: 61-74, 1974.
33. Martin A, Komada MR, and Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23: 117-145, 2003.
34. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 15: 326-330, 1997.
35. Murphy MP and Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 41: 235-250, 2000.
36. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Gates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
37. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, and Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958, 2000.
38. Ribatti D, Vacca A, Nico B, Roncali L, and Dammacco F. Postnatal vasculogenesis. Mech Dev 100: 157-163, 2001.
39. Risau W. Differentiation of endothelium. FASEB J 9: 926-933, 1995.
40. Risau W Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
41. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, and Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17: 189-212, 2001.
42. Salvemini D and Cuzzocrea S. Superoxide, superoxide dismutase and ischemic injury. Curr Opin Investig Drugs 3: 886-895, 2002.
43. Salvemini D and Riley DP. Nonpeptidyl mimetics of superoxide dismutase in clinical therapies for diseases. Cell Mol Life Sci 57: 1489-1492, 2000.
44. Salvemini D, Riley DP, and Cuzzocrea S. SOD mimetics are coming of age. Nat Rev Drug Discov 1: 367-374, 2002.
45. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, and Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 106: 571-578, 2000.
46. Schmidt AM, Yan SD, and Stern DM. The dark side of glucose. Nat Med 1: 1002-1004, 1995.
47. Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17-28, 2003.
48. Sharpe MA, Ollosson R, Stewart VC, and Clark JB. Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem J 366: 97-107, 2002.
49. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, and Fox RM. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339: 640-644, 1992.
50. Smith RA, Porteous CM, Coulter CV, and Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 263: 709-716, 1999.
51. Taniyama Y and Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075-1081, 2003.
52. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, and Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106: 2781-2786, 2002.
53. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, and Gurtner GC. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 105: 1068-1077, 2005.
54. Violi F, Loffredo L, Musella L, and Marcoccia A. Should antioxidant status be considered in interventional trials with antioxidants? Heart 90: 598-602, 2004.
55. West IC. Radicals and oxidative stress in diabetes. Diabet Med 17: 171-180, 2000.
56. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab 29: 579-585, 2003.
57. Yamagishi SI, Edelstein D, Du XL, and Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 50: 1491-1494, 2001.